Elan is a neuroscience-based biotechnology company headquartered in Dublin, Ireland. It was incorporated as a private limited company in December 1969 and became a public limited company in January 1984. Elan’s principal research and development, manufacturing and marketing facilities are located in Ireland and the United States.
Elan's BioNeurology work includes research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease and autoimmune diseases, including multiple sclerosis.
WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Jan. 26, 2012--
Biogen
Idec (NASDAQ: BIIB) and Elan
Corporation, plc (NYSE: ELN) today announced a global Phase 3b
study, ASCEND, that is being conducted to evaluate the effectiveness of
TYSABRI as a treatment for secondary-progressive multiple sclerosis
(SPMS). According to the National Multiple Sclerosis Society,
approximately half of all people initially diagnosed with
relapsing-remitting mult...
DUBLIN--(BUSINESS WIRE)--Jan. 25, 2012-- Elan Corporation, plc (NYSE:ELN) announced today that it will host a conference call on Wednesday, February 8, 2012 at 8:30 a.m. Eastern Standard Time (EST), 1:30 p.m. Greenwich Mean Time (GMT) with the investment community to discuss Elan’s fourth quarter and full-year 2011 financial results, which will be released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over the Internet a...
WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Jan. 20, 2012-- Today Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JCV antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal leukoence...
€3m Grant to Combine Business & Science Disciplines at UCD to Support
Skills Development in Biotechnology Sector
DUBLIN--(BUSINESS WIRE)--Dec. 12, 2011--
University College Dublin (UCD) and Elan Corporation plc, (NYSE: ELN) today
announced an initiative designed to create a leadership position in the
global biotechnology industry. The cornerstone of this effort will be
the establishment of Europe’s first interdisciplinary Chair in the ‘Bu...
RSS Feeds | 
E-mail Alerts | 
Contact IR